



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Falnidamol

Cat. No.:	HY-10322
CAS No.:	196612-93-8
Molecular Formula:	C ₁₈ H ₁₉ ClFN ₇
Molecular Weight:	387.84
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 31.25 mg/mL (80.57 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.5784 mL	12.8919 mL	25.7838 mL
		5 mM		0.5157 mL	2.5784 mL	5.1568 mL
		10 mM		0.2578 mL	1.2892 mL	2.5784 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.67 mg/mL (4.31 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC ₅₀ of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC ₅₀ =3.4 μM) and a range of other related tyrosine kinases (IC ₅₀ >10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity ^{[1][2]} .	
IC ₅₀ & Target	EGFR 3 nM (IC ₅₀)	ErbB2 3.4 μM (IC ₅₀)
In Vitro	Falnidamol (BIBX 1382) demonstrates antiproliferative activity in mitogenic assays performed with KB cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Falnidamol (BIBX 1382; p.o.; 10 mg/kg/day; 16 days) completely suppressed tumor growth of human A431 xenografts with respective a T/C value of 15% after 2 weeks of treatment ^[2] .	

Falnidamol (50 mg/kg/day for 2 weeks) results in dephosphorylation of the EGF receptor in A431 xenograft-bearing mice^[2]. With Falnidamol (p.o.; 10 mg/kg/day; 16 days), the C_{4h} is 2222 nM and the C_{24h} is 244 nM^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) with A431, FaDu, or HN5 cells ^[2]
Dosage:	10 mg/kg
Administration:	p.o.; daily; 16 days
Result:	Completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment.

Animal Model:	Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) with A431 cells ^[2]
Dosage:	10 mg/kg (Pharmacokinetic Analysis)
Administration:	p.o.; daily; 16 days
Result:	The C _{4h} is 2222 nM and the C _{24h} is 244 nM.

CUSTOMER VALIDATION

- Neurobiol Dis. 2020 Aug;142:104961.
- Front Mol Neurosci. 2018 Dec 6;11:447.
- Neuroscience. 2015 Jul 20;304:109-121.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9.
- [2]. Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA